Krystal Biotech, Inc. (NASDAQ:KRYS) Position Increased by LPL Financial LLC

LPL Financial LLC raised its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 156.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,946 shares of the company's stock after acquiring an additional 1,799 shares during the period. LPL Financial LLC's holdings in Krystal Biotech were worth $462,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Fox Run Management L.L.C. acquired a new stake in shares of Krystal Biotech during the fourth quarter worth about $339,000. KLP Kapitalforvaltning AS acquired a new position in Krystal Biotech during the fourth quarter worth $674,000. Summit Global Investments acquired a new stake in Krystal Biotech in the fourth quarter valued at $541,000. Teacher Retirement System of Texas grew its holdings in Krystal Biotech by 27.3% in the fourth quarter. Teacher Retirement System of Texas now owns 6,383 shares of the company's stock valued at $1,000,000 after purchasing an additional 1,369 shares during the last quarter. Finally, Privium Fund Management B.V. grew its holdings in Krystal Biotech by 45.7% in the fourth quarter. Privium Fund Management B.V. now owns 9,250 shares of the company's stock valued at $1,449,000 after purchasing an additional 2,900 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Activity at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by insiders.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock traded up $1.67 during trading on Monday, hitting $169.73. 167,657 shares of the stock were exchanged, compared to its average volume of 295,598. The stock's fifty day moving average is $176.37 and its 200 day moving average is $171.56. The stock has a market cap of $4.90 billion, a PE ratio of 56.77 and a beta of 0.75. Krystal Biotech, Inc. has a 12 month low of $141.72 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company's quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.30 earnings per share. Sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Citigroup upped their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research report on Thursday, February 20th. Jefferies Financial Group started coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target for the company. Chardan Capital boosted their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research report on Thursday, February 20th. HC Wainwright lifted their price objective on Krystal Biotech from $221.00 to $240.00 and gave the stock a "buy" rating in a report on Monday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $222.71.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).